RxDoctor Payments Data

Mark Amorosino, MD

Gastroenterology · Palm Beach Gardens, FLNPI 1316068554

Payments from drug & device makers

$14,441in general payments, 2019–2025

Across 532 payments — averaging $27.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Boston Scientific$1K
  • Medtronic$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Johnson & Johnson$987
  • Merz North America, Inc.$953
  • plus $6K from 32 others

What the payments were for

  • Travel & lodging$1,92013%
  • Food & beverage$12,43286%
  • Education$891%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,441 in reported general payments places this provider in the 75th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$165,333
Medicare patients
472
Services billed
1,367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase29$120,329
ZenpepLipase/Protease/Amylase14$63,589
LinzessLinaclotide37$45,211
ClenpiqSod Picosulf/Mag Ox/Citric Ac103$17,607
MovantikNaloxegol Oxalate13$5,027
Dexlansoprazole DrDexlansoprazole11$4,798
Ursodiol18$3,788
Omeprazole201$1,900
Dicyclomine Hcl74$1,187
Budesonide DrBudesonide11$958
Pantoprazole Sodium95$906
Esomeprazole Magnesium15$667
Amitriptyline Hcl44$499
Famotidine45$416
Ondansetron Hcl24$233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$2,601$165,54066 claims
Aimmune Therapeutics, Inc.Zenpep$200$63,58914 claims
Ferring Pharmaceuticals Inc.Clenpiq$178$17,607103 claims
Redhill Biopharma Inc.Movantik$375$5,02713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Palm Beach Gardens

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →